Venus Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth
10 Years:
1%
5 Years:
13%
3 Years:
3%
TTM:
21%
Compounded Profit Growth
10 Years:
-8%
5 Years:
28%
3 Years:
-10%
TTM:
37%
Stock Price CAGR
10 Years:
2%
5 Years:
72%
3 Years:
-9%
1 Year:
48%
Return on Equity
10 Years:
2%
5 Years:
6%
3 Years:
7%
Last Year:
6%
Last Updated: Unknown
Balance Sheet
Last Updated: Unknown
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Equity Capital
11
11
11
11
12
12
12
12
12
13
13
13
Reserves
364
450
445
426
376
350
320
311
374
427
447
474
Borrowings
271
289
321
335
312
307
298
220
51
43
42
41
Other Liabilities
72
84
64
70
65
82
102
100
118
97
98
98
Total Liabilities
718
834
841
843
765
751
733
644
556
580
601
627
Fixed Assets
401
439
444
452
406
389
364
289
262
241
216
219
CWIP
48
68
78
80
66
65
65
25
25
25
26
21
Investments
0
0
0
0
0
0
0
0
0
0
20
19
Other Assets
268
327
319
310
293
297
304
330
269
314
339
368
Total Assets
718
834
841
843
765
751
733
644
556
580
601
627
Reserves and Borrowings Chart
Cash Flow
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Cash from Operating Activity
52
53
68
47
59
31
45
78
132
41
37
37
Cash from Investing Activity
-104
-95
-67
3
-18
8
-11
-5
57
-17
-58
-8
Cash from Financing Activity
55
40
-1
-46
-44
-39
-35
-73
-162
-9
-1
-1
Net Cash Flow
3
-2
-1
3
-4
0
-1
-0
27
14
-22
28
Free Cash Flow
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Free Cash Flow
-151.00
-151.00
-232.00
-254.00
-261.00
-268.00
-265.00
-179.00
3.00
19.00
18.00
19.00
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
37
45
51
55
43
46
43
33
21
24
51
49
Inventory Days
178
173
194
219
226
246
286
296
129
118
132
125
Days Payable
26
38
40
38
48
52
72
77
76
47
56
45
Cash Conversion Cycle
190
180
204
236
221
240
257
252
74
95
127
129
Working Capital Days
98
115
146
179
163
144
127
166
74
85
112
130
ROCE %
15%
14%
6%
5%
2%
1%
1%
2%
8%
8%
8%
9%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Promoters
40.81%
40.81%
40.81%
40.81%
41.76%
41.76%
41.76%
41.76%
41.76%
41.76%
41.76%
41.76%
FIIs
0.02%
0.10%
0.28%
0.33%
0.96%
1.13%
1.07%
1.00%
0.98%
1.03%
1.59%
1.48%
Public
59.17%
59.09%
58.91%
58.86%
57.28%
57.11%
57.19%
57.26%
57.26%
57.21%
56.65%
56.76%
No. of Shareholders
14,419
16,617
18,231
19,952
21,189
22,015
22,243
21,719
20,498
19,267
19,560
19,913
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
FaceValue
10.00
10.00
10.00
10.00
10.00
Basic EPS (Rs.)
21.31
19.88
30.86
50.04
-8.10
Diluted EPS (Rs.)
21.31
19.88
30.86
50.04
-8.10
Cash EPS (Rs.)
41.08
44.04
55.55
78.63
17.84
Book Value[Excl.RevalReserv]/Share (Rs.)
364.66
344.38
329.50
324.33
262.01
Book Value[Incl.RevalReserv]/Share (Rs.)
364.66
344.38
329.50
324.33
262.01
Revenue From Operations / Share (Rs.)
449.85
415.58
447.86
444.11
274.94
PBDIT / Share (Rs.)
53.23
52.76
52.68
59.48
37.37
PBIT / Share (Rs.)
33.45
28.60
27.60
30.90
11.44
PBT / Share (Rs.)
33.39
28.38
27.24
39.34
-6.51
Net Profit / Share (Rs.)
21.31
19.87
30.47
50.04
-8.10
NP After MI And SOA / Share (Rs.)
21.31
19.87
30.47
50.04
-8.10
PBDIT Margin (%)
11.83
12.69
11.76
13.39
13.59
PBIT Margin (%)
7.43
6.88
6.16
6.95
4.15
PBT Margin (%)
7.42
6.82
6.08
8.85
-2.36
Net Profit Margin (%)
4.73
4.78
6.80
11.26
-2.94
NP After MI And SOA Margin (%)
4.73
4.78
6.80
11.26
-2.94
Return on Networth / Equity (%)
5.84
5.77
9.24
15.43
-3.09
Return on Capital Employeed (%)
8.17
7.37
7.57
8.31
3.36
Return On Assets (%)
4.54
4.41
7.02
11.11
-1.56
Long Term Debt / Equity (X)
0.07
0.08
0.08
0.11
0.22
Total Debt / Equity (X)
0.08
0.09
0.09
0.12
0.48
Asset Turnover Ratio (%)
0.97
0.90
1.01
0.86
0.46
Current Ratio (X)
4.53
3.91
3.00
2.38
1.32
Quick Ratio (X)
2.99
2.46
1.64
1.15
0.67
Inventory Turnover Ratio (X)
2.85
2.65
3.04
2.64
1.22
Interest Coverage Ratio (X)
790.78
239.55
146.41
5.64
3.46
Interest Coverage Ratio (Post Tax) (X)
317.56
91.24
85.67
3.94
0.91
Enterprise Value (Cr.)
409.63
205.06
351.82
361.07
183.27
EV / Net Operating Revenue (X)
0.68
0.36
0.58
0.65
0.54
EV / EBITDA (X)
5.76
2.91
5.00
4.92
3.97
MarketCap / Net Operating Revenue (X)
0.72
0.38
0.60
0.61
0.08
Price / BV (X)
0.89
0.47
0.81
0.84
0.08
Price / Net Operating Revenue (X)
0.72
0.38
0.60
0.61
0.08
EarningsYield
0.06
0.12
0.11
0.18
-0.36
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value: ₹364.89
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
Undervalued: 3.37% compared to the current price ₹353.00
Intrinsic Value: 307.67
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
Overvalued: 12.84% compared to the current price ₹353.00
Last 5 Year EPS CAGR: -15.68%
*Investments are subject to market risks
Strength and Weakness
Strength
Weakness
The company has higher reserves (397.00 cr) compared to borrowings (210.83 cr), indicating strong financial stability.
The company has shown consistent growth in sales (476.15 cr) and profit (20.38 cr) over the years.
The stock has a low average ROCE of 6.58%, which may not be favorable.
The stock has a high average Working Capital Days of 128.25, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 183.75, which may not be favorable.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Venus Remedies Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 5.84% (Industry Average ROE: 15.55%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 16.5 (Industry average Stock P/E: 51.31)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.08
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Venus Remedies Ltd. is a Public Limited Listed company incorporated on 15/09/1989 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1989PLC009705 and registration number is 009705. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 575.18 Cr. and Equity Capital is Rs. 13.37 Cr. for the Year ended 31/03/2022.
INDUSTRY
ADDRESS
CONTACT
Pharmaceuticals
S.C.O. 857, C. No. 10, 2nd Floor, Chandigarh Chandigarh 160101
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Venus Remedies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Manage Consent
We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
